City

Clinical trials near Birmingham, United States

Active studies with a listed research site in Birmingham, United States.

40active studies

17recruiting now

13countries represented

140largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowNot applicable

Time-restricted Eating for Postpartum Weight Loss

Postpartum Weight Retention, Overweight and ObesityCondition

Early Time-Restricted Eating (eTRE), ControlTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-06-29 · NCT06491537See eligibility →

Recruiting nowNot applicable

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

Gestational Diabetes, Pregnancy, High RiskCondition

Intensive glycemic targets, Standard glycemic targetsTreatment

United States5 locations

Indiana UniversitySponsor

Updated 2026-06-24 · NCT05124808See eligibility →

Recruiting nowPhase 2

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Type 2 DiabetesCondition

icovamenib 100 mg, PlaceboTreatment

United States17 locations

Biomea Fusion Inc.Sponsor

Updated 2026-06-15 · NCT07502508See eligibility →

Recruiting nowPhase 2, Phase 3

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

Obesity, Cardiovascular DiseasesCondition

Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet, Valsartan 80 mg Oral TabletTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-04-09 · NCT04971720See eligibility →

Recruiting nowNot applicable

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

Cardiovascular Diseases, Natriuretic PeptidesCondition

Study diet, Exercise capacity VO2 max determinationTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-04-09 · NCT05216042See eligibility →

Recruiting nowNot applicable

Ketogenic Diets for Weight Loss Maintenance: Impact on Energy Expenditure and Appetite in Individuals With Obesity

ObesityCondition

Diet Therapy, Calorie RestrictionTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-04-07 · NCT06736028See eligibility →

Recruiting nowNot applicable

CARBON: UAB Cardiovascular Research Biobank

Natriuretic Peptides, Cardiovascular DiseasesCondition

Intervention not listedTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-02-13 · NCT05067231See eligibility →

Recruiting nowPhase 3

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic FormCondition

Setmelanotide, PlaceboTreatment

United Kingdom, United States11 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-02-12 · NCT06760546See eligibility →

Recruiting nowNot applicable

FELLAShip to Better Health

High Blood Glucose, High CholesterolCondition

FELLAshipTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-01-22 · NCT07220213See eligibility →

Recruiting nowNot applicable

Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance

Obesity Prevention, Weight ChangeCondition

Reduced Food Variety (RFV), Home-based Resistance Training (HBRT)Treatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-01-07 · NCT06785064See eligibility →

Recruiting nowNot applicable

Inspire HER: Inspiring the Heart and Emotions for Radical Health

Cardiovascular-kidney-metabolic Syndrome, Cardiovascular DiseasesCondition

Inspire HER InterventionTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2025-12-29 · NCT06966258See eligibility →

Recruiting nowPhase 1, Phase 2

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Hypothalamic Obesity, Prader-Willi SyndromeCondition

Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)Treatment

United States7 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2025-12-22 · NCT06239116See eligibility →

Recruiting nowNot applicable

International Weight Control Registry

Weight Loss, OverweightCondition

Intervention not listedTreatment

United States7 locations

Tufts UniversitySponsor

Updated 2024-09-19 · NCT04907396See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Opening soonNot applicable

Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood

Obesity & Overweight, SarcopeniaCondition

High Protein Diet Counceling, Standard Protein Diet CouncelingTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-08-03 · NCT07446907See eligibility →

Opening soonPhase 2

Semaglutide for Low Back Pain

Lower Back Pain, Obesity (BMI>30)Condition

Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)Treatment

United States2 locations

Washington University School of MedicineSponsor

Updated 2026-07-28 · NCT07731256See eligibility →

Opening soonNot applicable

Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation

Weight Loss, GLP - 1Condition

Weight Loss Maintenance Program (Foundational), Mom's MealsTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-06-26 · NCT07535892See eligibility →

Opening soonNot applicable

Augmenting Primary Care-Based Obesity Management With the Nutu™ Digital Health Platform

Obesity & Overweight, Cardiovascular Risk FactorsCondition

FLOW Program, Nutu™ OfferTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-06-25 · NCT07404189See eligibility →

Opening soonPhase 2

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

Cardiovascular Diseases, Insulin Sensitivity/ResistanceCondition

Vericiguat 10 MG, PlaceboTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-01-23 · NCT06320951See eligibility →

Invitation onlyNot applicable

Evaluation of a Primary Care Based Lifestyle Medicine Clinic at UAB

Obesity and Obesity-related Medical ConditionsCondition

FLOW Lifestyle Medicine ClinicTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-05-22 · NCT06989281See eligibility →

Active, not recruitingNot applicable

Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

Kidney StoneCondition

Low Oxalate Diet before Weight Loss, Oral load of oxalate and sucralose before Weight LossTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-09-01 · NCT04633811See eligibility →

Active, not recruitingNot applicable

Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers

Kidney StoneCondition

Controlled Diet, Carbon-13 Oxalate and Sucralose IngestionTreatment

United States2 locations

University of Alabama at BirminghamSponsor

Updated 2026-08-26 · NCT04333745See eligibility →

Active, not recruitingPhase 3

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Hypothalamic ObesityCondition

Setmelanotide, PlaceboTreatment

Canada, Germany28 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-08-10 · NCT05774756See eligibility →

Active, not recruitingNot applicable

Development of an Inclusive Adaptive Treatment Strategy for Weight Loss in People With Prediabetes Using a Sequential Multiple Assignment Randomized Trial

Disabilities, Obesity and OverweightCondition

High Carbohydrate Diet, Reduced Carbohydrate DietTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-07-08 · NCT06976307See eligibility →

Active, not recruitingPhase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Adult Obesity, Weight ManagementCondition

ECC4703, PlaceboTreatment

United States15 locations

EccogeneSponsor

Updated 2026-06-25 · NCT07505303See eligibility →

Active, not recruitingPhase 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)Condition

Placebo, EnicepatideTreatment

Argentina, Canada70 locations

Carmot Therapeutics, Inc.Sponsor

Updated 2026-06-24 · NCT06628362See eligibility →

Active, not recruitingPhase 1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Obese But Otherwise Healthy ParticipantsCondition

CRB-913, PlaceboTreatment

United States15 locations

Corbus Pharmaceuticals Inc.Sponsor

Updated 2026-05-29 · NCT07310901See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Obesity, OverweightCondition

Bimagrumab, TirzepatideTreatment

United States12 locations

Eli Lilly and CompanySponsor

Updated 2026-05-26 · NCT06643728See eligibility →

Active, not recruitingNot applicable

Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women

Overweight or Obesity, Prediabetes or DiabetesCondition

Resistance TrainingTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-05-22 · NCT06360536See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

Active, not recruitingPhase 4

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

ObesityCondition

Naltrexone-Bupropion (NB) Combination, PlaceboTreatment

United States140 locations

Currax PharmaceuticalsSponsor

Updated 2026-03-31 · NCT06098079See eligibility →

Active, not recruitingNot applicable

Influence of Obesity on Endogenous Oxalate Synthesis

Kidney StoneCondition

controlled dietTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-03-19 · NCT03704350See eligibility →

Active, not recruitingPhase 2

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Endocrinology, Diabetes, Type IICondition

AZD6234, Placebo to matchTreatment

United States18 locations

AstraZenecaSponsor

Updated 2026-03-03 · NCT06851858See eligibility →

Active, not recruitingNot applicable

Probiotics and Insulin Resistance in Obese Asthmatics

Asthma, ObesityCondition

Probiotic, PlaceboTreatment

United States1 locations

University of Alabama at BirminghamSponsor

Updated 2026-01-16 · NCT05949255See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Phase 3

Weight LossCondition

VK2735Treatment

Puerto Rico, United States137 locations

Viking Therapeutics, Inc.Sponsor

Updated 2025-11-24 · NCT07104500See eligibility →

Active, not recruitingNot applicable

Stepping Into Lifestyle Changes

Overweight and Obesity, Pre-DiabetesCondition

Educational Group Weight Loss Classes, Home Gardening InterventionTreatment

United States2 locations

University of Alabama at BirminghamSponsor

Updated 2025-08-27 · NCT05625321See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Birmingham, United States

Current studies

Related cities